Small molecule inhibitors of the LEDGF site of human immunodeficiency virus integrase identified by fragment screening and structure based design

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Peat, Thomas S ^a   Rhodes, David I ^b,c   Vandegraaff, Nick ^b   Le, Giang ^b   Smith, Jessica A ^b   Clark, Lisa J ^b   Jones, Eric D ^b   Coates, Jonathan A V ^b   Thienthong, Neeranat ^b   Newman, Janet ^a   Dolezal, Olan ^a   Mulder, Roger ^a   Ryan, John H ^a   Savage, G Paul ^a   Francis, Craig L ^a   Deadman, John J ^b,d  

^a CSIRO   (Australia)

^b Avexa Ltd   (Australia)

^c JDJ Bioservices Ltd   (Australia)

^d Chemocopeia Ltd Carlton   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; INTEGRASE INHIBITOR; LENS EPITHELIUM DERIVED GROWTH FACTOR;

ARTICLE; CONTROLLED STUDY; CRYSTALLOGRAPHY; DRUG BINDING; DRUG BINDING SITE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PURIFICATION; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE;

BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; HIV; HIV INTEGRASE; HUMANS; IMMOBILIZED PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84863689623     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040147     Document Type: Article

References (49)

1. Ceccherini-Silberstein FC, Malet I, D'Arrigo R, Antinori A, Marcelin A-G, et al. (2009) Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 11: 17-29.
2. Croxtall JD, Scott LJ, (2010) Raltegravir: in treatment-naive patients with HIV-1 infection. Drugs 70: 631-642.
3. Jenkins TM, Hickman AB, Dyda F, Ghirlando R, Davies DR, et al. (1995) Catalytic domain of human immunodeficiency virus type 1 integrase: identification of a soluble mutant by systematic replacement of hydrophobic residues. Proc Natl Acad Sci USA 92: 6057-6061.
4. Goldgur Y, Dyda F, Hickman AB, Jenkins TM, Craigie R, et al. (1998) Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc Natl Acad Sci USA 95: 9150-9154.
5. Chen JC-H, Krucinski J, Miercke LJW, Finer-Moore JS, Tang AH, et al. (2000) Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci USA 97: 8233-8238.
6. Cherepanov P, Ambrosio AL, Rahman S, Ellenberger T, Engelman A, (2005) Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci USA 102: 17308-17313.
7. Wang J-Y, Ling H, Yang W, Craigie R, (2001) Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J. 20: 7333-7343.
8. Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, et al. (2010) Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nature Chemical Biology 6: 442-448.
9. Wielens J, Headey SJ, Jeevarajah D, Rhodes DI, Deadman J, et al. (2010) Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site. FEBS Lett 584: 1455-1462.
10. Rhodes DI, Peat TS, Vandegraaff N, Jeevarajah D, Le G, et al. (2011) Structural basis for a new mechanism of inhibition of HIV-1 integrase identified by fragment screening and structure-based design. Antiviral Chemistry and Chemotherapy 21: 155-168.
11. Schrijvers R, de Rijck J, Demeulemeester J, Adachi N, Vets S, et al. (2012) LEDGF/p75-Independent HIV-1 Replication Demonstrates a Role for HRP-2 and Remains Sensitive to Inhibition by LEDGINs. PLoS Path. 8: e1002558.
12. Kessl JJ, Jena N, Koh Y, Taskent-Sezgin H, Slaughter A, et al. (2012) A multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J. Biol. Chem 287: 16801-16811.
13. Cherepanov P, Maertens G, Proost P, Devreese B, van Beeumen J, et al. (2003) HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem 278: 372-381.
14. Cherepanov P, Sun Z-YJ, Rahman S, Maertens G, Wagner G, et al. (2005) Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nature Struct Mol Bio 12: 526-532.
15. Tsiang M, Jones GS, Hung M, Mukund S, Han B, et al. (2009) Affinities between the binding partners of the HIV-1 integrase dimer-lens epithelium-derived growth factor (IN dimer-LEDGF) complex. J Biol Chem 284: 33580-33599.
16. Rhodes DI, Peat TS, Vandegraaff N, Jeevarajah D, Newman J, et al. (2011) Crystal structures of novel allosteric peptide inhibitors of HIV integrase identify new interactions at the LEDGF binding site. ChemBiochem 12: 2311-2315.
17. Maertens G, Cherepanov P, Pluymers W, Busschots K, de Clercq E, et al. (2003) LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem 278: 33528-33539.
18. Hare S, Shun MC, Gupta SS, Valkov E, Engelman A, et al. (2009) A novel co-crystal structure affords the design of gain-of-function lentiviral integrase mutants in the presence of modified PSIP1/LEDGF/p75. PLoS Pathog 5: e1000259.
19. Madlala P, Gijsbers R, Christ F, Hombrouck A, Werner L, et al. (2011) Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression. AIDS 25: 1711-9.
20. Ballana E, Gonzalo E, Grau E, Iribarren JA, Clotet B, et al. (2012) Rare LEDGF/p75 genetic variants in white long-term nonprogressor HIV+ individuals. AIDS 26: 527-528.
21. Llano M, Vanegas M, Hutchins N, Thompson D, Delgado S, et al. (2006) Identification and characterization of the chromatin-binding domains of the HIV-1 integrase interactor LEDGF/p75. J. Mol. Biol. 360: 760-773.
22. Schröder AR, Shinn P, Chen H, Berry C, Ecker JR, et al. (2002) HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110: 521-529.
23. Ciuffi A, Llano M, Poeschla E, Hoffmann C, Leipzig J, et al. (2005) A role for LEDGF/p75 in targeting HIV DNA integration. Nat. Med. 11: 1287-1289.
24. McNeely M, Hendrix J, Busschots K, Boons E, Deleersnijder A, et al. (2011) In vitro DNA tethering of HIV-1 integrase by the transcriptional coactivator LEDGF/p75. J Mol Biol 410: 811-30.
25. de Luca L, Ferro S, Morreale F, de Grazia S, Chimirri A, (2011) Inhibitors of the interactions between HIV-1 IN and the cofactor LEDGF/p75. ChemMedChem 6: 1184-91.
26. Fan X, Zhang FH, Al-Safi RI, Zeng LF, Shabaik Y, et al. (2011) Design of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: a scaffold hopping approach using salicylate and catechol groups. Bioorg Med Chem 19: 4935-52.
27. de Luca L, Gitto R, Christ F, Ferro S, de Grazia S, et al. (2011) 4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process. Antiviral Res 92: 102-7.
28. Tsantrizos YS, Boes M, Brochu C, Fenwick C, Malenfant E, et al. (2007) 1-116, International Patent Application PCT/CA2007/000845.
29. Rocancourt D, Bonnerot C, Jouin H, Emerman M, Nicolas JF, (1990) Activation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J. Virol. 64: 2660-2668.
30. Chang T L-Y, Francois F, Mosoian M, Klotman ME, (2003) CAF-Mediated Human Immunodeficiency Virus (HIV) Type 1 Transcriptional Inhibition Is Distinct from α-Defensin-1 HIV Inhibition. J Virology 77: 6777-6784.
31. Papalia G, Myszka D, (2010) Exploring minimal biotinylation conditions for biosensor analysis using capture chips. Anal Biochem 403: 30-35.
32. Papalia GA, Giannetti AM, Arora N, Myszka DG, (2008) Thermodynamic characterization of pyrazole and azaindole derivatives binding to p38 mitogen-activated protein kinase using Biacore T100 technology and van't Hoff analysis. Anal Biochem 383: 255-264.
33. Giannetti AM, Koch BD, Browner MF, (2008) Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. J Med Chem 51: 574-580.
34. Deacon AM, Ellis PJ, Garman E, Gonzalez A, Sauter NK, et al. (2002) Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines. J Synchrotron Rad 9: 401-406.
35. Leslie AGW, (1992) Joint CCP4+ ESF-EAMCB Newsletter on Protein Crystallography 26.
36. Collaborative Computational Project Number 4 (1994) Acta Cryst. D 50: 760-763.
37. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Cryst 40: 658-674.
38. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Cryst. D 60: 2126-2132.
39. Murshudov GN, Vagin AA, Dodson EJ, (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Cryst. D 53: 240-255.
40. Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, et al. (2008) Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. Med Chem 51: 5843-5855.
41. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P, (2010) Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464: 232-236.
42. Baldanti F, Paolucci S, Gulminetti R, Brandolini M, Barbarini G, et al. (2010) Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. J Med Viol 82: 116-122.
43. Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, et al. (2006) An essential role for LEDGF/p75 in HIV integration. Science 314: 461-464.
44. McKee CJ, Kessl JJ, Shkriabai N, Dar MJ, Engelman A, et al. (2008) Dynamic modulation of HIV-1 integrase structure and function by cellular lens epithelium-derived growth factor (LEDGF) protein. J Biol Chem 283: 31802-31812.
45. Li M, Mizuuchi M, Burke TR Jr, Craigie R, (2006) Retroviral DNA integration: reaction pathway and critical intermediates. EMBO J 25: 1295-1304.
46. Cherepanov P, Devroe E, Silver PA, Engelman A, (2004) Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J Biol Chem 279: 48883-48892.
47. Vanegas M, Llano M, Delgado S, Thompson D, Peretz M, et al. (2005) Identification of the LEDGF/p75 HIV-1 integrase-interaction domain and NLS reveals NLS-independent chromatin tethering. J Cell Sci 118: 1733-1743.
48. de Rijck J, Vandekerckhove L, Gijsbers R, Hombrouck A, Hendrix J, et al. (2006) Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J Virol 80: 11498-11509.
49. Fitzkee NC, Torchia DA, Bax A, (2011) Measuring rapid hydrogen exchange in the homodimeric 36 kDa HIV-1 integrase catalytic core domain. Protein Sci 20: 500-512.